Texas Children’s Hospital Center for Vaccine Development (CVD)

Recombinant Protein COVID-19 Vaccine Technology

Since 2011, the BCM-Texas Children’s CVD has been developing recombinant protein coronavirus vaccines for SARS and MERS, and in 2020 developed the first recombinant protein COVID-19 through microbial fermentation in yeast.  The technology has been transferred to 4 entities to date: India (Biological E, CORBEVAX), Indonesia (BioFarma, CORONAVAC), Bangladesh (Incepta) and Botswana (ImmunityBio). In India and Indonesia, more than 100 million doses of these vaccines have been administered. CORBEVAX has also been authorized as an adult heterologous booster.  To date there are 8 scientific publications about laboratory development of the BCM-Texas Children’s CVD recombinant protein COVID-19 vaccine (in addition to 5 others on SARS/MERS (not shown), and 3 on the clinical trials see below):

The published results from the clinical trials performed by Biological E Ltd. can be found in the following peer-reviewed articles: 

Heterologous Booster Dose with
CORBEVAX following Primary Vaccination with
COVISHIELD Enhances Protection against SARS-CoV-2